Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Zynerba Pharmaceuticals, Inc. (ZYNE)
|
Add to portfolio |
|
|
|
| Price: |
$4.13
| | Metrics |
| OS: |
53.9
|
M
| |
-130
|
% ROE
|
| Market cap: |
$223
|
M
| |
|
|
|
Net cash:
|
$36
|
M
| |
$0.67
|
per share
|
|
EV:
|
$187
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($38.6)
|
M
| |
|
|
|
EBIT
|
($38.8)
|
M
| |
|
|
| EPS |
($0.81)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.3 |
| Revenue growth | | | | -100.0% | | -100.0% | -97.4% | -65.6% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.3 |
| Gross margin | | | | | 100.0% | | 100.0% | 100.0% |
| Research and development | 21.1 | 21.4 | 35.7 | 20.4 | 27.2 | 22.8 | 16.8 | 7.4 |
| General and administrative | 14.2 | 15.3 | 16.4 | 13.9 | 13.2 | 10.0 | 6.4 | 5.4 |
| EBIT | -35.3 | -36.8 | -52.1 | -34.3 | -40.4 | -32.8 | -23.3 | -12.5 |
| EBIT margin | | | | | -46974.2% | | -321472.8% | -4493.1% |
| Pre-tax income | -35.0 | -37.3 | -51.3 | -32.9 | -39.9 | -32.0 | -23.4 | -12.5 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | |
| Net income | -35.0 | -37.3 | -51.3 | -32.9 | -39.9 | -32.0 | -23.4 | -12.6 |
| Net margin | | | | | -46408.3% | | -322600.1% | -4500.3% |
| |
| Diluted EPS | ($0.82) | ($0.95) | ($1.90) | ($1.50) | ($2.61) | ($2.48) | ($2.58) | ($2.82) |
| Shares outstanding (diluted) | 42.7 | 39.3 | 27.0 | 22.0 | 15.3 | 12.9 | 9.1 | 4.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|